BioSpace News Archive

Vaccinex, Inc. today announced that its licensee, Surface Oncology (NASDAQ: SURF, “Surface”) dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s ActivMAb.

XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures.

Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 am PT / 12:00 pm ET.

LinKinVax is announcing capital funding for a total of €7,3 M from several individual tech executive investors including the co-founder André-Jacques Auberton-Hervé and its newest investor In-Q-Tel, Inc., the non-profit strategic investor which delivers cutting-edge and critically needed technology capabilities that contribute to the national security of the United States and its allies.

Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly System able to detect five common respiratory pathogens at once.

ImmuCell Corporation announced preliminary, unaudited sales results for the year ended December 31, 2022.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first vitiligo patient has been dosed in a Phase 1a/b clinical trial of VYN201.

NeuroPace, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors.

OrthoPediatrics Corp. announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2022, and provided 2023 financial guidance.

REGENXBIO Inc. announced the promotion of Curran Simpson from Chief Technology and Operations Officer to Chief Operating Officer.